Summit Therapeutics announces clinical trial collaboration with GSK to evaluate Ivonescimab in combination with GSK’s B7-H3 antibody drug conjugate (ADC)

CAR-T Digest - August 2020

Weekly Digest - January 2026

12 January 2026: Summit Therapeutics announces clinical trial collaboration with GSK to evaluate Ivonescimab in combination with GSK’s B7-H3 antibody drug conjugate (ADC)

Summit Therapeutics announced a clinical trial collaboration with GSK to evaluate Ivonescimab, its investigational PD-1/VEGF bispecific antibody, in combination with GSK’s B7-H3–targeting antibody drug conjugate Risvutatug rezetecan across multiple solid tumor indications, including small cell lung cancer
The collaboration reflects a shared focus on exploring novel combination strategies that may improve outcomes beyond current treatment options, with Summit aiming to accelerate the development of Ivonescimab across a broader range of solid tumors
Under the agreement, the combination will be evaluated for safety and preliminary anti-tumor activity in several tumor settings, with the goal of understanding how dual immune modulation and targeted cytotoxic delivery may work together in difficult-to-treat cancers
Summit will supply Ivonescimab for the study, while GSK will oversee day-to-day clinical trial operations, with both companies retaining full rights to their respective assets under a mutually non-exclusive arrangement
Clinical trials under this collaboration are expected to initiate patient dosing in mid-2026, marking an important step in expanding combination development opportunities for Ivonescimab alongside GSK’s next-generation ADC portfolio